Skip to main content
For US Healthcare Professionals Only
Quick Links
Prescribing Information
BIMZELX® (bimekizumab-bkzx)
CIMZIA® (certolizumab pegol)
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
Adverse Event Reporting
Report an Adverse Event or Product Complaint
Email
1-844-599-CARE (2273)
Connect with an MSL
Connect With Us
Main navigation
Home
Our Science
Publications
Clinical Pipeline
Opportunities for Investigators
Disease Education
Dermatology
Rare Disease
Rheumatology
Podcasts
Congress Materials
Medical Information
HCP Resources
Prescribing Information
Connect With an MSL
Connect With Us
BIMZELX® (bimekizumab-bkzx)
CIMZIA® (certolizumab pegol)
RYSTIGGO® (rozanolixizumab-noli)
ZILBRYSQ® (zilucoplan)
Home
Congress Materials
Myasthenia Gravis Foundation of America (MGFA) Scientific Session at AANEM, 2023
< Back to search results
Risk of myasthenia gravis exacerbation and level of healthcare resource utilization by Myasthenia Gravis Activities of Daily Living score
View PDF
Download